Quantum Biopharma (QNTM) Asset Writedowns and Impairment (2020 - 2023)

Quantum Biopharma (QNTM) posted Asset Writedowns and Impairment of $236186.0 for Q4 2023, down 93.85% sequentially from $3.8 million in Q2 2023.

Quantum Biopharma (QNTM) Asset Writedowns and Impairment (2020 - 2023) Analysis & Trends

Quantum Biopharma has reported Asset Writedowns and Impairment for 2 years, with the latest figure at $236186.0 in Q4 2023.

Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $236186.0 in Q4 2023, while the trailing twelve-month figure through Dec 2024 was $236186.0 (down 94.82% YoY) and the FY2023 annual result came in at $4.6 million, changed N/A from the prior year.
Asset Writedowns and Impairment eased to $236186.0 in Q4 2023 per QNTM's latest filing, from $3.8 million in the prior quarter.
Over five years, Asset Writedowns and Impairment peaked at $3.8 million in Q2 2023 and troughed at $22202.8 in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Quantum Biopharma	15.44 Mn	11.80 Mn	-

Download Data